Shield Therapeutics PLC Board Change (6956Q)
September 14 2017 - 2:01AM
UK Regulatory
TIDMSTX
RNS Number : 6956Q
Shield Therapeutics PLC
14 September 2017
Shield Therapeutics plc
("Shield" or the "Group")
Board Change
London, UK, 14(th) September 2017: Shield Therapeutics plc
(LSE:STX), a specialty pharmaceutical company focused on secondary
care, announces that Joanne Estell, has resigned her Board position
and as Chief Financial Officer ("CFO") and Company Secretary to
pursue other business interests outside the healthcare sector.
A search process for a new CFO has commenced and the Board has
appointed Dr Karl Keegan as interim Chief Financial Officer with
immediate effect. Dr Keegan has a background of senior financial
positions in the specialty pharmaceutical sector and in his
previous capacity as Director of Corporate Development, has worked
closely with Joanne, Shield's Leadership Team and the Board on all
aspects of the Group's operations and strategy development. They
will work together through to the end of October to deliver a
smooth and effective transition.
Dr Keegan has previously held CFO positions at Pharma Group NV,
and Minster Pharmaceuticals plc, as well as managerial roles at
SmithKline Beecham (now GlaxoSmithKline). Dr Keegan also spent over
12 years as a sell-side analyst at UBS, Bank of America, Canaccord,
and Dresdner Kleinworth Benson.
Carl Sterritt, Founder and Chief Executive Officer of Shield
Therapeutics, said: "On behalf of the Board, I thank Joanne for her
contributions to the growth of Shield as a publicly listed company,
particularly her role in the recent financing. We are fortunate and
pleased to be able to appoint Karl as interim CFO. He is a
well-qualified and suitably sector-experienced internal successor
to Joanne and we look forward to working with Karl on Shield's
continued success. We look forward to updating investors on recent
progress within the business on 20 September when we publish our
interim results."
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive Officer
Karl Keegan, Chief Financial Officer
Nominated Advisor and Joint Broker +44 (0)203 100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker +44 (0)207 418 8900
Peel Hunt LLP
James Steel/Dr Christopher Golden
Financial PR Advisor
+44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
US Investor Relations
Lazar Partners +1 (212) 867 1762
Fern Lazar/ David Carey
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company
focused on the commercialisation and development of late-stage,
hospital-focused pharmaceuticals which address areas of unmet
medical need. Our clear purpose is to help our patients become
people again, by enabling them to enjoy the things that make the
difference in their everyday lives. The Group has a marketed
product, Feraccru(R), for the treatment of iron deficiency anaemia
(IDA) in adult patients with inflammatory bowel disease (IBD) which
has exclusive IP rights until the mid-2030's. Shield Therapeutics,
headquartered in London, is listed on LSE's AIM under the ticker
STX. For more information please visit
www.shieldtherapeutics.com.
About Feraccru(R)
Feraccru is Shield's lead product and is a novel therapy for the
treatment of IDA. Feraccru received marketing authorisation across
Europe in February 2016 for the treatment of IDA in adult patients
with IBD and is in the early stages of commercialisation in
European markets. The Group is currently completing a pivotal Phase
3 clinical trial of Feraccru in IDA patients with pre-dialysis CKD
and expects to announce results of this study around the turn of
the year. A positive result is expected to facilitate the filing of
an NDA for Feraccru in the US as well as significantly broader
commercialisation in Europe and beyond.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUOUARBBAKAUR
(END) Dow Jones Newswires
September 14, 2017 02:01 ET (06:01 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2023 to Apr 2024